PF-Atlas › Clinical Trials › NCT02874989
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
Dasatinib + Quercetin · Phase 1
Registry ID
NCT02874989
Phase
Phase 1
Status
Completed
Drug / intervention
Dasatinib + Quercetin
Sponsor
Wake Forest University Health Sciences
Start
2016-12-16
Enrollment
26
Locations
2
About this trial
The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well tolerated in patients with IPF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02874989 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.